Updated data from the ongoing OCTAVE study show, for the first time, the real-world vaccine responses and infection outcomes in clinically at-risk patients with a range of immunocompromised or immunosuppressed conditions.
Preliminary data from the landmark OCTAVE study in August 2021 showed that a significant proportion of clinically at-risk patients with immunocompromised or immunosuppressed conditions, mounted a low, or undetectable, immune response after two doses of the same SARS-CoV-2 vaccine. Now, in new peer-reviewed data, researchers are able to share the real-world infection outcomes for this clinically at-risk group.
This new Nature Medicine publication reports on the OCTAVE trial, a collaboration between the Universities of Glasgow, Birmingham and Oxford and a consortium of other leading UK institutions, and contains important new data on infection rates, disease severity and deaths in the patient groups, who were studied up to one year after their first vaccination. Data from the study cover the time period from 2021 to mid-2022, and include patients infected with the alpha, delta and omicron strains of SARS-CoV-2. The data do not estimate the impact of third and fourth vaccinations, which have since been offered to patients in the groups studied.
These new data show that while in most at-risk patient groups the overall COVID-19 infection rates were low, the risk of severity and death from SARS-CoV-2 was high in a sub-group of conditions, despite vaccination. This was particularly the case during the Delta wave. Furthermore, the data show that while Omicron, now the dominant SARS-CoV-2 strain worldwide, saw a rise of infection rate among at-risk patients, fewer of them became severely unwell or died.
The OCTAVE findings in detail
- There were 20 hospital sites across the UK who enrolled 2686 patients with reduced function of their immune systems to the trial.
- Overall, 474 patients in the study became ill with COVID-19 up to one year after the date of their first vaccination. 111 of these infections were identified as either Alpha (1) or Delta (110) variants and 336 were identified as Omicron. 48 people were admitted to hospital because of a COVID-19 infection and sadly, 15 people died from the disease.
- Most infections (76%) occurred more than six months after the second vaccination and were in patients with a kidney transplant, inflammatory arthritis and Crohn’s Disease. The majority of these infections were also first-time SARS-CoV-2 infections. Infections occurring within six months of the second vaccination were not more severe than those reported six months or longer post second vaccination.
- Most infections (90%) were mild in severity, including some asymptomatic cases. Severe cases requiring hospitalisation or death was reported in 9.8% of infections and occurred predominantly in patients with renal disease. Patients infected in the Delta wave were more likely to have serious infection than those infected in the Omicron wave.
- In patients who did not mount a successful immune response to two COVID-19 vaccinations, the rate of infection was higher when compared to those in the study that did mount an immune response after vaccination.
- In some disease groups, the overall infection rates were low – possibly because of continued shielding at the time – but the proportion of severe cases within these groups were high. This was most notable in patients with ANCA Associated Vasculitis on rituximab, auto and allogeneic stem cell transplant and CART-T cell treated patients.
- Low rates of severe disease were reported in patients with Crohn’s disease and ulcerative colitis.
OCTAVE (Observational Cohort Trial-T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2) is a multi-centre, UK-wide trial led by the University of Glasgow, co-ordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit and delivered by a national consortium of leading academic and clinical centres. It was set up in the middle of the COVID-19 pandemic to evaluate, in real time, the immune responses following COVID-19 vaccination in patients with immune-mediated inflammatory diseases such as cancer, inflammatory arthritis, diseases of the kidney or liver, or patients who are having a stem cell transplant.
Previously, preliminary data released from OCTAVE in 2021 showed that while most patients mounted a successful immune response after two doses of the vaccine, some patients with certain immunosuppressed conditions mounted a low, or undetectable, immune response. The study found that overall 12% of patients on the trial failed to develop antibodies, with an additional 27% only generating low levels of antibodies. Some patients also failed to generate adequate T cell responses after vaccination. Vaccine failure rates were higher in some subgroups including patients with ANCA-associated vasculitis on the drug rituximab, patients receiving haemodialysis and also on immunosuppressive therapy, and patients who were solid organ transplant recipients.
The study used a variety of state-of-the-art immune tests performed on blood samples taken before and/or after COVID-19 vaccination, as well as infection and severity data on patients to better understand the real-world impact of a low vaccination response in these patient groups.
In the UK, more than 60% of people aged over 65 were known to have one or more chronic disease in 2019, while more than 12 million people aged 18-65 were living with a chronic condition lasting longer than 12 months. Government estimates suggest that around 500,000 people have an immune suppressive disease in the UK – a significant group which may be more at risk of severe COVID-19 infection if not fully protected by vaccination.
Professor Iain McInnes, lead of the OCTAVE trial, and Vice Principal and Head of the College of MVLS at the University of Glasgow, said: “The OCTAVE study has provided vital insights into the effectiveness of SARS-CoV-2 directed vaccines in some of our most vulnerable patient groups. The study’s key strengths include identifying the small number of patients who may not respond to the vaccines, enabling healthcare providers and policy makers to make the best decisions to protect these groups of people. Importantly the study has also been able to reassure us that the majority of our immunocompromised patients in the UK have been protected from severe COVID-19 by the vaccination programme.”
Professor Pamela Kearns, Director of the Cancer Research UK Clinical Trials Unit at the University of Birmingham said: “OCTAVE provides an important understanding of how vaccines provided protection for many groups of the most clinically vulnerable, and how the variants of the disease affected how effective they were.
“We can see that there are areas of particular concern where vaccines didn’t adequately protect against COVID 19, including some patients with renal diseases and some inflammatory conditions.
“We’re immensely grateful for all those participants and each of the centres that took part to give us the clearest picture yet of how the most clinically vulnerable were protected, and where there are areas of weakness that need to be addressed.”
Professor Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Nuffield Department of Medicine, University of Oxford, said: “Importantly, both the T cells and Antibody responses to vaccines were shown to protect against severe disease in immunocompromised patients.”
Dr Jonathan Pearce, Director of Strategy & Planning, Medical Research Council said: “The important findings of the OCTAVE study where critically enabled by the collaborative efforts of researchers, hospitals and participants from across the UK. Their combined commitment ensured that the study provided robust insights of value to our response to COVID-19 and for our preparation for future pandemics”.
Professor Andrew Ustianowski, NIHR Clinical Lead for the COVID-19 Vaccination Programme and Joint National Infection Specialty Lead said: “COVID-19 is no longer the major problem that it was, largely as a result of the UK’s world-leading vaccination research programme and roll-out.
“Vaccines however do not always provide equal protection in all our individuals, especially those with poor immune systems.
“The OCTAVE study has been pivotal in informing us on how best we should protect subgroups of our populations most at risk, so that we do not leave anyone behind in our fight to better protect all from the ongoing threat of coronavirus.”
The OCTAVE trial is one of the largest studies in the world so far into post-SARS-CoV-2 vaccination in immunocompromised patients and is funded by the Medical Research Council (MRC). OCTAVE is a collaborative research project involving groups in the Universities of Glasgow, Birmingham, Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust.
The study, ‘SARS-CoV-2 specific humoral and T cell responses and clinical outcomes following COVID-19 vaccination in patients with immune suppressive disease-a phase-III multicentre study-OCTAVE’ is published in Nature Medicine.